Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Halesway

- PMLiVE

NICE set to knock-back Amgen’s myeloma treatment Kyprolis

Cites uncertainty in clinical and cost-effectiveness analyses

Bristol Myers Squibb logo

BMS wins early UK access for Opdivo in Hodgkin’s lymphoma

Cancer treatment approved by the MHRA for use before EU licence in place

- PMLiVE

‘Hard’ Brexit could mean a longer wait for new drugs, says report

Warns of deprioritised status if negotiators fail to secure access to the single market

- PMLiVE

The Global Awards 2016 finalists announced

GSW Worldwide’s virtual reality epilepsy campaign among the 145 shortlisted entries

- PMLiVE

UK to cut wait to innovative treatments by four years

Proposals in the Accelerated Access Review aim to speed up access to innovation

- PMLiVE

Halesway changes name to FCB Halesway

Move aligns agency more closely with its parent company FCB Health

Bristol-Myers Squibb (BMS) building

NICE turns down Opdivo but offers CDF hope

Wants more cost-effectiveness data to be gathered

- PMLiVE

NICE rejects Imbruvica for non-Hodgkin’s lymphoma

Draft guidance cites insufficient cost-effectiveness evidence for J&J’s drug

National Institute for Health and Care Excellence NICE logo

NICE to create fast track for most cost-effective new drugs

Proposes accelerated appraisal process for drugs with QALY of £10,000 or less

- PMLiVE

Health activators lack confidence in primary healthcare

Survey finds patient decision-makers increasingly turning to non-traditional sources

- PMLiVE

Regional NHS pulmonary rehabilitation video campaign launched

Aims to boost referral rates among GPs in the north east of England

- PMLiVE

UCB launches UK product helpline for patients and HCPs

UCBCares will answer treatment queries and use feedback to drive innovation

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links